TY - JOUR
T1 - Extremely Preterm Infant Admissions Within the SafeBoosC-III Consortium During the COVID-19 Lockdown
AU - Rasmussen, Marie Isabel
AU - Hansen, Mathias Lühr
AU - Pichler, Gerhard
AU - Dempsey, Eugene
AU - Pellicer, Adelina
AU - EL-Khuffash, Afif
AU - A, Shashidhar
AU - Piris-Borregas, Salvador
AU - Alsina, Miguel
AU - Cetinkaya, Merih
AU - Chalak, Lina
AU - Özkan, Hilal
AU - Baserga, Mariana
AU - Sirc, Jan
AU - Fuchs, Hans
AU - Ergenekon, Ebru
AU - Arruza, Luis
AU - Mathur, Amit
AU - Stocker, Martin
AU - Otero Vaccarello, Olalla
AU - Szczapa, Tomasz
AU - Sarafidis, Kosmas
AU - Królak-Olejnik, Barbara
AU - Memisoglu, Asli
AU - Reigstad, Hallvard
AU - Rafińska-Ważny, Elżbieta
AU - Hatzidaki, Eleftheria
AU - Peng, Zhang
AU - Gkentzi, Despoina
AU - Viellevoye, Renaud
AU - De Buyst, Julie
AU - Mastretta, Emmanuele
AU - Wang, Ping
AU - Hahn, Gitte Holst
AU - Bender, Lars
AU - Cornette, Luc
AU - Tkaczyk, Jakub
AU - del Rio, Ruth
AU - Fumagalli, Monica
AU - Papathoma, Evangelia
AU - Wilinska, Maria
AU - Naulaers, Gunnar
AU - Sadowska-Krawczenko, Iwona
AU - Lecart, Chantal
AU - Couce, María Luz
AU - Fredly, Siv
AU - Heuchan, Anne Marie
AU - Karen, Tanja
AU - Greisen, Gorm
N1 - Funding Information:
The sponsor/coordinating investigator, Professor of Paediatrics GG, is the initiator of the SafeBoosC-III project. He has no financial interest in the results of the trial. The Elsass Foundation, Aage and Johanne Louis-Hansen Foundation, and Svend Andersen Foundation supported the SafeBoosC-III trial through unconditional and unrestricted grants of DKK 3,300,000, DKK 1,000,000 and DKK 1,000,000, respectively. These funding sources had no role in the design of this study and will not have any role during its execution, analysis, interpretation of the data or decision to submit results.
Publisher Copyright:
© Copyright © 2021 Rasmussen, Hansen, Pichler, Dempsey, Pellicer, EL-Khuffash, A, Piris-Borregas, Alsina, Cetinkaya, Chalak, Özkan, Baserga, Sirc, Fuchs, Ergenekon, Arruza, Mathur, Stocker, Otero Vaccarello, Szczapa, Sarafidis, Królak-Olejnik, Memisoglu, Reigstad, Rafińska-Ważny, Hatzidaki, Peng, Gkentzi, Viellevoye, De Buyst, Mastretta, Wang, Hahn, Bender, Cornette, Tkaczyk, del Rio, Fumagalli, Papathoma, Wilinska, Naulaers, Sadowska-Krawczenko, Lecart, Couce, Fredly, Heuchan, Karen and Greisen.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/12
Y1 - 2021/7/12
N2 - Objective: To evaluate if the number of admitted extremely preterm (EP) infants (born before 28 weeks of gestational age) differed in the neonatal intensive care units (NICUs) of the SafeBoosC-III consortium during the global lockdown when compared to the corresponding time period in 2019. Design: This is a retrospective, observational study. Forty-six out of 79 NICUs (58%) from 17 countries participated. Principal investigators were asked to report the following information: (1) Total number of EP infant admissions to their NICU in the 3 months where the lockdown restrictions were most rigorous during the first phase of the COVID-19 pandemic, (2) Similar EP infant admissions in the corresponding 3 months of 2019, (3) the level of local restrictions during the lockdown period, and (4) the local impact of the COVID-19 lockdown on the everyday life of a pregnant woman. Results: The number of EP infant admissions during the first wave of the COVID-19 pandemic was 428 compared to 457 in the corresponding 3 months in 2019 (−6.6%, 95% CI −18.2 to +7.1%, p = 0.33). There were no statistically significant differences within individual geographic regions and no significant association between the level of lockdown restrictions and difference in the number of EP infant admissions. A post-hoc analysis based on data from the 46 NICUs found a decrease of 10.3%in the total number of NICU admissions (n = 7,499 in 2020 vs. n = 8,362 in 2019). Conclusion: This ad hoc study did not confirm previous reports of a major reduction in the number of extremely pretermbirths during the first phase of the COVID-19 pandemic. Clinical Trial Registration: ClinicalTrial.gov, identifier: NCT04527601 (registered August 26, 2020), https://clinicaltrials.gov/ct2/show/NCT04527601.
AB - Objective: To evaluate if the number of admitted extremely preterm (EP) infants (born before 28 weeks of gestational age) differed in the neonatal intensive care units (NICUs) of the SafeBoosC-III consortium during the global lockdown when compared to the corresponding time period in 2019. Design: This is a retrospective, observational study. Forty-six out of 79 NICUs (58%) from 17 countries participated. Principal investigators were asked to report the following information: (1) Total number of EP infant admissions to their NICU in the 3 months where the lockdown restrictions were most rigorous during the first phase of the COVID-19 pandemic, (2) Similar EP infant admissions in the corresponding 3 months of 2019, (3) the level of local restrictions during the lockdown period, and (4) the local impact of the COVID-19 lockdown on the everyday life of a pregnant woman. Results: The number of EP infant admissions during the first wave of the COVID-19 pandemic was 428 compared to 457 in the corresponding 3 months in 2019 (−6.6%, 95% CI −18.2 to +7.1%, p = 0.33). There were no statistically significant differences within individual geographic regions and no significant association between the level of lockdown restrictions and difference in the number of EP infant admissions. A post-hoc analysis based on data from the 46 NICUs found a decrease of 10.3%in the total number of NICU admissions (n = 7,499 in 2020 vs. n = 8,362 in 2019). Conclusion: This ad hoc study did not confirm previous reports of a major reduction in the number of extremely pretermbirths during the first phase of the COVID-19 pandemic. Clinical Trial Registration: ClinicalTrial.gov, identifier: NCT04527601 (registered August 26, 2020), https://clinicaltrials.gov/ct2/show/NCT04527601.
KW - COVID-19
KW - extremely preterm
KW - neonatal intensive care unit admission
KW - observational study
KW - pandemic
KW - randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=85111256604&partnerID=8YFLogxK
U2 - 10.3389/fped.2021.647880
DO - 10.3389/fped.2021.647880
M3 - Journal article
C2 - 34322460
AN - SCOPUS:85111256604
VL - 9
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
SN - 2296-2360
M1 - 647880
ER -